Hamel Ernest, Day Billy W, Miller John H, Jung M Katherine, Northcote Peter T, Ghosh Arun K, Curran Dennis P, Cushman Mark, Nicolaou K C, Paterson Ian, Sorensen Erik J
Toxicology and Pharmacology Branch, Developmental Threapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute at Frederick, MD 21702, USA.
Mol Pharmacol. 2006 Nov;70(5):1555-64. doi: 10.1124/mol.106.027847. Epub 2006 Aug 3.
Previous studies on the drug content of pelleted tubulin polymers suggest that peloruside A binds in the laulimalide site, which is distinct from the taxoid site. In a tubulin assembly system containing microtubule-associated proteins and GTP, however, peloruside A was significantly less active than laulimalide, inducing assembly in a manner that was most similar to sarcodictyins A and B. Because peloruside A thus far seems to be the only compound that mimics the action of laulimalide, we examined combinations of microtubule-stabilizing agents for synergistic effects on tubulin assembly. We found that peloruside A and laulimalide showed no synergism but that both compounds could act synergistically with a number of taxoid site agents [paclitaxel, epothilones A/B, discodermolide, dictyostatin, eleutherobin, the steroid derivative 17beta-acetoxy-2-ethoxy-6-oxo-B-homo-estra-1,3,5(10)-trien-3-ol, and cyclostreptin]. None of the taxoid site compounds showed any synergism with each other. From an initial study with peloruside A and cyclostreptin, we conclude that the synergism phenomenon derives, at least in part, from an apparent lowering of the tubulin critical concentration with drug combinations compared with single drugs. The apparent binding of peloruside A in the laulimalide site led us to attempt construction of a pharmacophore model based on superposition of an energy-minimized structure of peloruside A on the crystal structure of laulimalide. Although the different sizes of the macrocycles limited our ability to superimpose the two molecules, atom correspondences that were observed were consistent with the difficulty so far experienced in creation of fully active analogs of laulimalide.
先前关于微管蛋白聚合物颗粒药物含量的研究表明,peloruside A结合在laulimalide位点,该位点与紫杉烷类位点不同。然而,在含有微管相关蛋白和GTP的微管蛋白组装系统中,peloruside A的活性明显低于laulimalide,其诱导组装的方式与sarcodictyins A和B最为相似。由于peloruside A似乎是迄今为止唯一能模拟laulimalide作用的化合物,我们研究了微管稳定剂组合对微管蛋白组装的协同作用。我们发现,peloruside A和laulimalide没有协同作用,但这两种化合物都能与多种紫杉烷类位点药物[紫杉醇、埃坡霉素A/B、盘状海绵醇、双硫代他汀、刺参素、甾体衍生物17β-乙酰氧基-2-乙氧基-6-氧代-B-高雌甾-1,3,5(10)-三烯-3-醇和环链菌素]协同作用。紫杉烷类位点的化合物彼此之间均未显示出任何协同作用。通过对peloruside A和环链菌素的初步研究,我们得出结论,协同作用现象至少部分源于与单一药物相比,药物组合使微管蛋白临界浓度明显降低。peloruside A在laulimalide位点的明显结合促使我们尝试基于peloruside A的能量最小化结构与laulimalide晶体结构的叠加构建药效团模型。尽管大环的不同大小限制了我们叠加这两个分子的能力,但观察到的原子对应关系与迄今为止在创建laulimalide的完全活性类似物时遇到的困难一致。
Bioorg Med Chem Lett. 2004-10-4
Angew Chem Int Ed Engl. 2014-1-27
Cancer Drug Resist. 2019-3-19
Cancers (Basel). 2021-12-12